Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study
Kevin C. Flanagan, Eric J. Duncavage(Washington University in St. Louis), Jessica Ley(Washington University in St. Louis), Karim Welaya(CoxHealth), Bruce Bank, Ida Deichaite(Moores Cancer Center), Xingwei Sui(Providence Regional Cancer Partnership), Howard L. McLeod(Unknown), Vera Vavinskaya(University of California San Diego), Jarret Glasscock(Cofactor Genomics (United States)), William H. Westra(Mount Sinai Hospital), Jon Earls(Cofactor Genomics (United States)), Warren L. Alexander(William Beaumont Army Medical Center), Georges Azzi(Holy Cross Hospital), D. Messina(Cofactor Genomics (United States)), O. Kenneth Macdonald(Cancer Care Northwest), Todd D. Shenkenberg(Valley Baptist Medical Center), Katharine A. Price(WinnMed), Douglas Adkins(Washington University in St. Louis), James L. Wade(American Society of Clinical Oncology), Jennifer N. Slim(MultiCare Health System), A. Dimitrios Colevas(Cancer Institute (WIA)), Leisa Sutton(Moores Cancer Center), Rachel L. Wellinghoff(Cofactor Genomics (United States)), Michelle Ponder(Cofactor Genomics (United States)), Jeffrey Hiken(Cofactor Genomics (United States)), Ezra E.W. Cohen(Moores Cancer Center), Andrew W. Pippas, Steven E. Kossman
Cited by 9
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i>
|Science|2011|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k